TP53 and B-cell chronic lymphocytic leukemia: Although, in CLL, ibrutinib has proven to be efficacious in relapse/refractory patients and in high risk patients with TP53 deletion or mutation (29, 30) resistance and important adverse effects have been reported over the years.